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WE HAVE PREVIOUSLY demonstrated that the proliferation of established human glioma cell lines correlated with 
protein kinase C (PKC) activity and that a relatively selective PKC inhibitor, staurosporine, inhibits glioma cell 
proliferation. The purpose of this study was to determine whether low-passage glioma cell lines were also sensitive 
to staurosporine and to compare the antimitotic effects of staurosporine with tamoxifen, an antiestrogen with a 
known PKC inhibitory effect presently being investigated in the treatment of recurrent glioma. We measured the 
effects of treatment with staurosporine or tamoxifen on the proliferation rate of five established glioma cell lines 
(A172, U251, U87, U373, U563) and four low-passage glioma cell lines. The proliferation of all cell lines was 
inhibited by staurosporine, at an IC50 value (concentration at which activity is 50% inhibited) of approximately
2 nmol/L. All established lines, but only one low-passage line, were susceptible to tamoxifen, with an ICS0 value 
of 10 |imol/L. Three of the four low-passage lines were poorly inhibited by tamoxifen. The IC50 values for the 
inhibition of cellular proliferation by staurosporine and tamoxifen closely corresponds to the IC50 data for the 
inhibition of particulate PKC activity in gliomas. We conclude that staurosporine is more effective in the inhibition 
of glioma proliferation than tamoxifen and that staurosporine is potentially useful in the adjuvant treatment of 
gliomas. The correspondence in ICS0 results for proliferation and PKC activity further strengthens the hypothesis 
that an aberrant PKC system in gliomas drives their hyperproliferative state. (Neurosurgery 33:495-501, 1993) 
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P revious studies in this laboratory have demonstrated that used chemotherapeutic agent with known PKC inhibitory ac- 
1) established glioma cell lines have very high protein tion (14, 20, 25) is tamoxifen, an antiestrogenic agent widely 
kinase C (PKC) activity when compared with non-ma- used in the adjuvant treatment of breast carcinoma (7, 13). 
lignant adult >uman glia; 2) the proliferation rate of glioma cell Pollack et al. (22) have demonstrated that tamoxifen can de­
lines is highly correlated with their particulate and total PKC crease the proliferation of established as well as low-passage 
activity (r = 0.94 and 0.98, respectively); and 3) the prolifer- glioma cell lines. Those authors proposed that the decrease in 
ation of the Al 72 glioma cell line is susceptible to inhibition by cellular proliferation was secondary to PKC inhibition, al- 
the relatively selective PKC inhibitor staurosporine (8, 9, 11). though PKC enzyme activity was not assessed. Vertosick et al. 
These observations have led us to postulate that an aberrant (29) have observed increased survival after treatment with ta- 
PKC system in gliomas drives their intrinsic hyperproliferative moxifen in patients with recurrent glioma. We have recently 
state and that PKC inhibitors may be useful as adjuvant therapy reported that high-dose tamoxifen therapy in a patient with 
for malignant gliomas. Indeed, the intratumoral administration recurrent glioblastoma produced tumor regression and clinical 
of staurosporine in rats harboring the C6 glioma have signif- stabilization (2).
icantly extended survival rates and increased general motor In view of the reports that the IC50 (concentration at which
activity, when compared with sham controls (10). A currently activity is 50% inhibited) of tamoxifen for PKC inhibition was
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in the micromolar range (20), whereas the equivalent IC50 tor 
staurosporine was in the nanomolar range (15, 26), we have 
directly compared the efficacy of staurosporine with that of 
tamoxifen on the cellular proliferation of five established gli­
oma cell lines. In order to account for the highly clonal status 
of established cell lines, which might not be truly representa­
tive of the cellularly heterogeneous glioblastoma multiforme, 
four low-passage glioma cell lines were used as a closer ap­
proximation of the in vivo state. The results demonstrate that 
on a molar basis, staurosporine is 3 orders of magnitude more 
effective than tamoxifen in inhibiting cellular proliferation and 
PKC activity. In addition, although the proliferation of all of the 
low-passage cell lines was susceptible to staurosporine, three 
of four low-passage lines were not significantly altered by 
tamoxifen. These results suggest that staurosporine (21) is po­
tentially more useful than tamoxifen in the adjuvant treatment 
of patients with gliomas.
MATERIALS AND METHODS 
Cell lines
The established glioma cell lines were A172, U87-MG, 
U251-MG, U563-MG, and U373-MG. These are well-charac­
terized, long-term lines courtesy of V. P. Collins (Ludwig In­
stitute for Cancer Research, Stockholm, Sweden) (6). Cells 
were of a relatively homogenous population, as determined by 
morphological criterion, presumably as the result of clonal 
selection with repeated passages.
Fresh glioblastoma specimens were obtained from the op­
erating room and were histologically confirmed by a neuro­
pathologist. Tumor specimens were minced into small pieces of 
1 mm3 or less and were allowed to adhere and grow on a culture 
dish coated with 10 jug of poly-l-lysine per milliliter. Cell lines 
were passaged at confluency via gentle trypsinization and were 
used for study on the second or third passage. Glial fibrillary 
acidic protein immunohistochemistry was done on all of the 
low-passage lines. All contained cells positive for glial fibrillary 
acidic protein.
The cell lines were maintained in feeding medium consisting 
of 10% fetal bovine serum; gentamicin, 20 Mg/ml; glutamine, 
1 mmol/L; pyruvate, 1 mmol/L; 0.1% dextrose; and essential 
amino adds buffered to pH 7.4 (all medium constituents were 
purchased from GIBCO, Grand Island, New York). The cell 
lines were fed twice a week and passaged when confluent by 
gentle trypsinization (0.05%).
Assessment of cell proliferation
The assessment of cell proliferation was performed by two 
techniques: [3H]thymidine incorporation and counting of cell 
numbers. To assess [3H]thymidine incorporation, cells were 
seeded onto 12-mm glass coverslips at a density of 10,000 per 
coverslip; plating was considered as Day 1 of the experiment. 
Six hours later, after cells had adequately adhered, the cover­
slips were flooded with the medium described above. Each 
coverslip was pulsed with 1 fiCi of [3H]thymidine for 6 hours 
before being harvested at various times postseeding (see Re­
sults). The method of harvesting coverslips for the measure­
ment of [3H]thymidine incorporation has been previo 
scribed; results were read as counts per minute (9). To j 
dose-response curves, sister cultures were treated wit 
ent concentrations of either staurosporine or tamoxife 
hours before harvest at Day 5. In another set of expe 
the duration of staurosporine and tamoxifen treatmeri 
from 6 to 36 hours, and the resultant rate of proliferat 
tabulated.
To assess cell numbers, cell line A172 was plate< 
million cells per 100-mm culture plate. To generate 
response curve, sister cultures were treated with differ^  
centrations of staurosporine for 48 hours before harves
5. At predetermined times, cells were gently trypsini2 
lected and counted on a hemocytometer.
Protein kinase C assay
Measurement of the A172 cell line PKC enzyme actn 
by a histone phosphorylation assay where the rate of [32 
phate transferred into lysine-rich histone was quantify 
has been previously described in detail (9).
RESULTS
[3H]thymidine incorporation is a good 
indicator of changes in cell numbers
We have previously reported that nonmalignant n  
mouse astrocytes treated with inhibitors or promoters 
tosis showed corresponding changes in their rates of p 
ation that could be comparably detected by three d  
methods: changes in cell numbers, [3H]thymidine upt 
bromodeoxyuridine incorporation (35). Because malign 
oma cells can quadruple their deoxyribonucleic acid « 
without mitosis, creating an aneuploid glioblast, it was 
tant to demonstrate that [3H]thymidine incorporation v\ 
a reliable indicator of the proliferation of glioma cells. Tt 
Al 72 cell line was plated and cellular proliferation was a 
at different days postseeding. Figure 1 showed that [s 
midine incorporation corresponds well (r = 0.96) with c 
in cell number. This correspondence was also true fo: 
cells treated with staurosporine, counted, and correlate 
the dose-response curve for A172 shown in Figure 2 (r = 
On the basis of these observations, we have therefor 
[3H]thymidine incorporation as an index of cell proliferal 
the rest of the studies,
Comparison of the inhibition of glioma cell 
proliferation with staurosporine and tamoxifen
The five established glioma cell lines A172, U87, 
U251, and U373 with different basal rates of proliferatio 
all sensitive to inhibition by staurosporine with IC50 
between 1 and 4 nmol/L (Fig. 2). The individual IC50 
obtained from computer-generated best-fit curves we
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A. Tritiated Thymidine Incorporation Is A Good 
Indicator Of Cell Proliferation:
Thymidine Uptake Vs. Cell Number Of A172 Cells




B. Correlation Of Thymidine Uptake With 
Cell Numbers
CELL NUMBER (MILLION)
FIGURE t. Correspondence of [3H]thymidine uptake with 
changes in cell numbers. In Panel A, the amount of 
[3H]thymidine incorporation after a 6-hour pulse at differ­
ent time periods postseeding on Day 1 (n = 3 coverslips 
per point) was compared with changes in cell numbers 
(n = 4) at corresponding intervals. The standard error was 
less than 10% of the mean. These data were submitted to 
regression analysis in Panel B to give a correlation coeffi­
cient of 0.96 (P < 0.001).
spectively, A172 (2.75 nmol/L), U87 (2 nmol/L), U373 (3.5 
nmol/L), U251 (1 nmol/L), and U563 (1 nmol/L). The inhi­
bition of the proliferation of cell line A172 was evident by 12 
hours of treatment with staurosporine and plateaued by 24 
hours (Fig. 3). In addition to the established cell lines, all four 
low-passage cell lines were sensitive to staurosporine in ap­
proximately the same concentrations as were the established 
cell lines (Fig. 4). Individual IC50 values were, respectively, 
W342, 7.5 nmol/L; W362, 1 nmol/L; W363, 6 nmol/L; and 
W368, 1 nmol/L.
In comparison with staurosporine, tamoxifen treatment also 
reduced the proliferation of all five established glioma cell lines 
(Fig. 5). However, the IC50 values were approximately 10 
Mmol/L on average. In further contrast to staurosporine, ta­
moxifen treatment of up to 10 ,umol/L did not substantially 








FIGURE 2. Proliferation of glioma cell lines is sensitive to 
staurosporine inhibition in a dose-related manner. Stauro­
sporine was administered for 48 hours at the doses indi­
cated. Values are the mean of four coverslips, with the 
standard error less than 10% of the mean. In the absence 
of staurosporine, control counts-per-minute (cpm) values 
(± standard error) were A172, 18,703 ± 1,073; U563, 
14,977 ± 1,140; U251, 51,801 ±  3,037; U87, 14,460 + 
1,420; (J373, 27,838 ± 1,345. IC50 values were taken from 
dose-response curves that represented the best-fit curves. 
Data for 100 nmol of staurosporine per liter, which were 
10% or less of controls, are not shown in the graph in or­
der that the effects at lower concentrations can be clearly 
discerned.
Time Course Of Inhibition By





Period Of Treatment (h)
FIGURE 3. Time course of action of PKC inhibitors on the 
proliferation of the A172 glioma cell line. Each point is the 
mean of four coverslips, with the standard error less than 
10% of the mean in all cases. SP, staurosporine; TMX, ta­
moxifen.
Correspondence of cell proliferation with protein 
kinase C activity
Measurements of the PKC activity of the A172 glioma cell 
line after staurosporine treatment revealed that, although cy­
tosolic activity was unaffected, particulate PKC activity was 
substantially reduced (Fig. 7a). Correlation analysis of partic­
ulate PKC activity with [3H]thymidine incorporation after stau­
rosporine treatment resulted in an r value of 0.85 (Fig. 7b). The 
ICS0 for the inhibition of particulate PKC activity was 1.5
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Low Passage Glioma Cell Lines 
Are Sensitive To Staurosporine
One Of Four Low Passage Cell Lines 
Is Inhibited By Tamoxifen
s>x
Staurosporine (nmol/L)
FIGURE 4. Low-passage glioma cell lines are sensitive to 
inhibition by staurosporine. Each point is the mean of four 
coverslips, with the standard error less than 20% of the 
mean in all cases. Control rates of proliferation (± stan­
dard error) were: W342, 1364 ± 212; W362, 4430 ± 199; 
W363, 1746 ±  310; and W368, 1703 ± 214.







FIGURE 5. Established glioma cell lines are also sensitive 
to inhibition by tamoxifen. Each point is the mean of four 
coverslips, with the standard error less than 10% of the 
mean in all cases.
nmol/L, which closely corresponds to the IC50 for proliferation 
(2 nmol/L). Similarly, tamoxifen treatment of the A172 cells 
resulted in a diminution of particulate PKC activity, with an 
IC50 value of 5.6 /imol/L (Fig. 8).
Comparison of the effects of staurosporine on 
the proliferation of glioma cells and neonatal 
rat astrocytes
Proliferation rates were measured in neonatal rat astrocytes 






FIGURE 6. Proliferation of only one of four low-passage 
glioma cell lines is substantially inhibited by tamoxifen.
Each point is the mean of four coverslips, with the stan­
dard error less than 10% of the mean in all cases.
the A172 glioma cell line. Glioma cell lines were marginally 
more sensitive to staurosporine, with an IC50 of 2 nmol/L, than 
were rat astrocytes, which had an IC50 of 5 nmol/L (Fig. 9).
DISCUSSION
The multitude of reports on the abnormal expression of 
growth factors such as epidermal growth factor in glioma cells 
(1,31) raises the question of how extracellular signals provided 
by ligand-receptor interactions are transduced to the nucleus of 
the cell effecting proliferation. The interaction of epidermal 
growth factor with its receptor-tyrosine kinase complex results 
in numerous events, including autophosphorylation at the in­
tracellular SH2 domain and activation of a series of enzymes 
including phospholipase C -y  (19). Phospholipase C-y activa­
tion results in diacylglycerol and inositol triphosphate forma­
tion. Whereas the latter mobilizes calcium from intracellular 
stores, diacylglycerol goes on to activate PKC, a phospholipid- 
dependent serine-threonine kinase composed of at least 10 
known isoforms (19). The isoforms demonstrate differences in 
their enzymological properties, differential tissue expression, 
and specific intracellular localization (19). An integrated no­
menclature has been developed to categorize the PKC isoforms 
on the basis of their mode of activation. The group A isoforms 
consist of the four classical PKCs: a, fil, /3II, and y. The group 
B isoforms consist of four new PKCs (PKC): 5, e, t?(L), and 6. The 
group C isoforms consist of two atypical PKCs (PKC): f  and A. 
PKC has been implicated in various functions in the central 
nervous system including proliferation of astrocytes (34), pro­
cess formation in oligodendrocytes (32), and long-term poten­
tiation in neurons (3). The finding that the tumor-promoting 
phorbol esters acted via PKC led us to investigate its role in 
transformed glia (17, 18, 30). We have reported that the en­
zymatic activities of PKC in glioma cells are at least 3 orders of 
magnitude higher than those of nonmalignant adult human 
glia and that the proliferation rates of five established glioma 
cell lines are highly correlated with their PKC activity (r = 0.98)
(9). In addition, the relatively selective PKC inhibitor stauro-
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A. Effects Of Staurosporine On PKC Activity 
And Proliferation Of A172 Glioma Cell Line
Effects Of Tamoxifen On PKC Activity And 
Proliferation Of A172 Glioma Cell Line
Staurosporine (nmol/L)













FIGURE 8. Effect of tamoxifen on the proliferation rate 
and PKC activity of the A172 glioma cell line. See legend 
to Figure 7.
A172 Glioma Cell Line Is Marginally More 




[ HJTHYMIDINE (% of Controls)
FIGURE 7. Effect of staurosporine on the proliferation rate 
and PKC activity of the A172 glioma cell line. PKC activity 
(in picomoles per minute per milligram of protein) was as­
sayed in triplicate. Control cytosolic PKC value was 
1314± 127, whereas control particulate PKC activity was 
303 ± 86. Control [3H]thymidine incorporation was 18,703 
± 1,073. In Panel B, the particulate PKC activity was corre­
lated with [3H]thymidine incorporation to give a correla­
tion coefficient of 0.85.
sporine (12,16, 21,23) could inhibit basal proliferation as well 
as block the effect of mitogens of glioma cells (9, 11).
Previous studies from this laboratory had investigated the 
effect of staurosporine on one human (Al 72) and one rat (C6) 
glioma cell line (9). In this study, we have extended the ex­
periments to five established glioma lines of different basal
Staurosporine (nmol/L)
FIGURE 9. The A172 glioma cell line is marginally more 
sensitive to staurosporine inhibition than are neonatal rat 
astrocytes. Preparation of neonatal rat astrocytes has been 
previously described (30, 31). Each point is the mean of 
four coverslips, with the standard error less than 10% of 
the mean in all cases. Control rate of proliferation (± stan­
dard error) for neonatal rat astrocytes was 12,408 ±  508.
proliferation rates (9) and have found them all to be equally 
sensitive to staurosporine (Fig. 2). A  common criticism of using 
established cell lines is that they are highly clonally selected 
and are not representative of the in vivo state. This is especially 
true in high-grade glioma, in which there is cellular heteroge­
neity, hence, the name glioblastoma multiforme. Therefore, we 
have further examined low-passage glioma cell lines as a closer 
approximation of the in vivo state. The results show that all of 
the low-passage lines were inhibited by staurosporine in ap­
proximately the same concentrations as the established cell 
lines (Fig. 3).
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The inhibition of glioma cell proliferation by staurosporine 
occurred at concentrations that inhibited PKC (Fig. 7); for A l 72, 
the IC50 of staurosporine for proliferation (2 nmol/L) closely 
corresponds to the IC50 for the inhibition of PKC (1.5 nm ol/L). 
Such data lend further support to the contention that PKC is 
intimately involved in regulating the proliferation of glioma 
cells. It must be noted that staurosporine is "relatively" selec­
tive, also inhibiting protein kinase A and tyrosine kinases, 
however, at higher concentrations than those required to in­
hibit PKC (15). Interestingly, we found that it was the partic­
ulate fraction of PKC that was inhibited by staurosporine (Fig. 
7a). This correlation is in keeping with the concept that the 
particulate form of PKC represents the active form of the en­
zyme (17, 18). Further studies will determine if a particular 
isoform is intimately involved in regulating proliferation in 
these neoplasms (4, 27).
Comparisons of the effects of staurosporine on glioma cells 
and neonatal rat astrocytes indicate that staurosporine is mar­
ginally more effective in inhibiting proliferation of the malig­
nant cells. Whether this may provide a therapeutic window for 
effective chemotherapy without much associated cerebral tox­
icity remains unknown; adult human astrocytes have a very 
low rate of proliferation in vitro when compared with neonatal 
rat astrocytes (33-35) and conceivably will be less susceptible 
to the inhibitory effects of staurosporine; however, this as­
sumes that the toxicity of this relatively selective agent is re­
lated to its inhibition of PKC. This possibility will be examined 
in detail with analogs with increased selectivity for PKC.
There has been much recent interest in tamoxifen because it 
has been extensively used in the treatment of breast cancer and 
recently in the treatment of malignant melanoma (5). Tamox­
ifen is tolerated in high doses, giving concentrations in plasma 
in the micromolar range (5, 28). Its secondary effects are well 
known, and it crosses the blood-brain barrier. Vertosick et al. 
(29) have demonstrated increased survival of patients with 
recurrent glioma who are using tamoxifen. We have treated a 
patient with recurrent glioblastoma with high-dose tamoxifen 
and have observed tumor regression and clinical stabilization 
(2).
We studied the effects of tamoxifen on five established and 
four low-passage cell lines. Although tamoxifen inhibited cell 
proliferation in all of the established lines, its effectiveness was 
in the micromolar concentration, as opposed to the nanomolar 
concentration required by staurosporine. The PKC enzyme as­
say demonstrated an IC50 of 5.6 /zmol/L for tamoxifen (Fig. 7), 
in dose correspondence with its IC50 for the inhibition of gli­
oma cell proliferation (10 ^mol/L). Three of four low-passage 
cell lines were, however, not inhibited by tamoxifen, in contrast 
to staurosporine, which inhibited all of the lines. The reasons 
for this tamoxifen resistance is not immediately apparent; a 
prediction would be that some gliomas are not susceptible to 
tamoxifen. This was borne out by the study of Vertosick et al. 
(29), in which some but not all of the patients with malignant 
gliomas showed a response to tamoxifen. Although w e have 
reported a case of tumor regression (2), w e have subsequently 
treated two patients with recurrent glioma w ho had no re­
sponse to high-dose tamoxifen. We are presently conducting a
Phase 2 cooperative study on the effect of high-dose 
on recurrent glioma.
In conclusion, the close correspondence of the IC50 
the inhibition of proliferation and PKC activity for I 
rosporine and tamoxifen supports the hypothesis tl- 
PKC activity in glioma cells drives their high rate o: 
ation and that these drugs decrease proliferation by i 
the PKC system. Comparative in vitro studies of stau 
with tamoxifen as inhibitors of glioma proliferatioi 
that staurosporine is a potentially more useful d n  
adjuvant therapy of patients with malignant gliomas 
sporine has been previously shown to inhibit the g  
human cervical carcinoma cells, as well as product 
inhibition of human bladder carcinoma cells, a humai 
elocytic leukemia line (HL-60), and bovine endothelis 
cells at concentrations that correlate well with in v; 
inhibition (15). Staurosporine has also been shown t 
the invasion of human bladder carcinoma cells, sugges 
it may play a role in other aspects of the malignant p t  
(24). Furthermore, staurosporine has demonstrated ai 
activity against human carcinoma xenografts in nude n  
Indeed, we have demonstrated increased survival in ai 
model of brain tumor in rats with implanted C6 glio  
staurosporine treatment, with little evidence of neuri
(10). However, this study was preliminary, and furthe 
trials are in progress with different animal glioma in  
well as various modes of staurosporine administratior 
human trials can be considered.
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COMMENT
In the attempt to find more effective approaches to the bio­
chemical control of glioma growth, it is critical to establish new 
targets for potential therapeutic agents. The protein kinase C 
pathway has become one of these potentially useful targets. It 
is clear from many different studies that the protein kinase C 
pathway is somehow a factor in affecting glioma growth.
In this study, the authors extend their earlier observations by 
studying five low-passage human glioma lines, rather than a 
single high-passage line, and compare a highly selective in­
hibitor of protein kinase C activity, staurosporine, with a less- 
selective agent, tamoxifen. The findings are suggestive of a 
modest but apparent difference in effectiveness, with stauro­
sporine being shown to be the more useful age'nt. These find­
ings are of interest because they serve to add more data to our 
understanding of a new and potentially useful target for de­
veloping strategies to control glioma cell growth.
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